

Stephen Devereux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6245809/publications.pdf>

Version: 2024-02-01

134
papers

7,299
citations

116194

36
h-index

62345

84
g-index

134
all docs

134
docs citations

134
times ranked

7285
citing authors

#	ARTICLE	IF	CITATIONS
1	TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. <i>Blood</i> , 2021, 137, 3064-3078.	0.6	20
2	The architecture of neoplastic follicles in follicular lymphoma; analysis of the relationship between the tumor and follicular helper T cells. <i>Haematologica</i> , 2020, 105, 1593-1603.	1.7	28
3	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> , 2020, 34, 787-798.	3.3	321
4	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020, 135, 1204-1213.	0.6	130
5	Continued Long Term Responses to Ibrutinib + Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial. <i>Blood</i> , 2020, 136, 17-18.	0.6	11
6	Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2722-2729.	0.8	197
7	Toxicity and efficacy of alemtuzumab combined with CHOP for aggressive T-cell lymphoma: a phase 1 dose-escalation trial. <i>Leukemia and Lymphoma</i> , 2019, 60, 2291-2294.	0.6	2
8	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019, 94, 554-562.	2.0	27
9	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <i>Blood Advances</i> , 2019, 3, 1799-1807.	2.5	90
10	Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study. <i>Blood</i> , 2019, 134, 3039-3039.	0.6	1
11	<i>In vitro</i> and <i>in vivo</i> evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia. <i>Haematologica</i> , 2018, 103, 497-505.	1.7	8
12	A multicentre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, prolymphocytic leukaemia or mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018, 182, 429-433.	1.2	23
13	A retrospective analysis of post-transplant lymphoproliferative disorder following liver transplantation. <i>European Journal of Haematology</i> , 2018, 100, 98-103.	1.1	6
14	Calcium-RasGRP2-Rap1 signaling mediates CD38-induced migration of chronic lymphocytic leukemia cells. <i>Blood Advances</i> , 2018, 2, 1551-1561.	2.5	31
15	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. <i>American Journal of Hematology</i> , 2018, 93, 1402-1410.	2.0	24
16	Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 803-813.e7.	0.2	32
17	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. <i>Haematologica</i> , 2018, 103, 1502-1510.	1.7	111
18	Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure. <i>Blood</i> , 2018, 132, 181-181.	0.6	5

#	ARTICLE	IF	CITATIONS
19	Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study. <i>Blood</i> , 2018, 132, 182-182.	0.6	20
20	Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).. <i>Journal of Clinical Oncology</i> , 2018, 36, 7521-7521.	0.8	0
21	Outcome for patients with relapsed/refractory aggressive lymphoma treated with gemcitabine and oxaliplatin with or without rituximab; a retrospective, multicentre study. <i>Leukemia and Lymphoma</i> , 2017, 58, 2051-2056.	0.6	7
22	The Myeloma Patient Outcome Scale is the first quality of life tool developed for clinical use and validated in patients with follicular lymphoma. <i>European Journal of Haematology</i> , 2017, 98, 508-516.	1.1	7
23	Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids. <i>Journal of Clinical and Translational Endocrinology</i> , 2017, 9, 18-20.	1.0	8
24	Preliminary Results of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a First-in-Human Trial (CALM) in Adult Patients with CD19+ Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2017, 130, 887-887.	0.6	22
25	<scp>ALK</scp>â€positive large Bâ€cell lymphoma with strong <scp>CD</scp>30 expression; a diagnostic pitfall and resistance to brentuximab and crizotinib. <i>Histopathology</i> , 2016, 69, 880-882.	1.6	12
26	<scp>NCRI</scp> phase <scp>II</scp> study of <scp>CHOP</scp> in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. <i>British Journal of Haematology</i> , 2016, 175, 43-54.	1.2	53
27	Phenotype and immune function of lymph node and peripheral blood CLL cells are linked to transendothelial migration. <i>Blood</i> , 2016, 128, 563-573.	0.6	27
28	Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2016, 374, 323-332.	13.9	785
29	Outcomes of Ibrutinib Therapy By Age in Patients with CLL/SLL: Analyses from Phase 3 Trial Data (RESONATE and RESONATE-2). <i>Blood</i> , 2016, 128, 2041-2041.	0.6	4
30	Addition of Obinutuzumab to Ibrutinib Enhances Depletion of CLL Cells in the Peripheral Blood and Bone Marrow after 1 Month of Combination Therapy: Initial Results from the Bloodwise TAP Icicle Extension Study. <i>Blood</i> , 2016, 128, 2049-2049.	0.6	1
31	Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 234-234.	0.6	36
32	Integrated and Long-Term Safety Analysis of Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL). <i>Blood</i> , 2016, 128, 4383-4383.	0.6	7
33	Outcomes with ibrutinib by line of therapy in patients with CLL: Analyses from phase III data.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7520-7520.	0.8	10
34	Chronic Lymphocytic Leukemia Cells Express CD38 in Response to Th1 Cellâ€Derived IFN-Î³ by a T-betâ€Dependent Mechanism. <i>Journal of Immunology</i> , 2015, 194, 827-835.	0.4	40
35	Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3KÎ inhibition. <i>Leukemia</i> , 2015, 29, 744-747.	3.3	20
36	Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation: Analysis of 533 Adult Patients Who Underwent Transplantation at King's College Hospital. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 60-66.	2.0	62

#	ARTICLE	IF	CITATIONS
37	Diffuse Large B-Cell Lymphoma (DLBCL) Tumor Cells Reprogram Lymphatic Fibroblasts into Cancer-Associated Fibroblasts (CAFs) That Contribute to Tumor Microenvironment (TME)-Driven Immune Privilege. <i>Blood</i> , 2015, 126, 1474-1474.	0.6	2
38	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM). <i>Blood</i> , 2015, 126, 495-495.	0.6	2
39	In-Vivo Labelling Studies in Patients with Chronic Lymphocytic Leukemia Studies Demonstrate the Existence of Apparently Distinct Subpopulations That Differ in Phenotype and Proliferative Capacity. <i>Blood</i> , 2015, 126, 615-615.	0.6	2
40	CC-122 Repairs T Cell Activation in Chronic Lymphocytic Leukemia That Results in a Concomitant Increase in PD-1:PD-L1 and CTLA-4 Immune Checkpoint Expression at the Immunological Synapse. <i>Blood</i> , 2015, 126, 1738-1738.	0.6	1
41	Rho and Rap guanosine triphosphatase signaling in B cells and chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1993-2001.	0.6	6
42	Development and characterization of a physiologically relevant model of lymphocyte migration in chronic lymphocytic leukemia. <i>Blood</i> , 2014, 123, 3607-3617.	0.6	31
43	Long-Term Outcomes of Alemtuzumab-Based Reduced-Intensity Conditioned Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous Leukemia Secondary to Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 111-117.	2.0	27
44	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 213-223.	13.9	1,427
45	Long term follow-up of BEAM-autologous and BEAM-alemtuzumab allogeneic stem cell transplantation in relapsed advanced stage follicular lymphoma. <i>Leukemia Research</i> , 2014, 38, 737-743.	0.4	7
46	How to treat patients with relapsed chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 163, 423-435.	1.2	4
47	Chronic lymphocytic leukaemia. <i>Medicine</i> , 2013, 41, 278-281.	0.2	0
48	Outcome of Donor Lymphocyte Infusion after T Cell-depleted Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 562-568.	2.0	78
49	Lymphadenopathy and splenomegaly in an HIV-infected man. <i>Journal of Clinical Virology</i> , 2013, 56, 265-268.	1.6	0
50	Analysis Of T Cell Receptor Repertoire Reveals Evidence For Antigen-Specific Response In CLL Lymph Nodes. <i>Blood</i> , 2013, 122, 4141-4141.	0.6	0
51	Characterization Of a Novel In Vitro Circulation System Designed To Model The Migration Of Primary CLL Cells Across The Vascular Endothelium. <i>Blood</i> , 2013, 122, 667-667.	0.6	0
52	Targeting The T Cell Component Of The Tumour Microenvironment In Chronic Lymphocytic Leukaemia; A Potential Therapeutic Strategy. <i>Blood</i> , 2013, 122, 4147-4147.	0.6	0
53	Lymph Node Derived CLL Cells Have a More Activated Phenotype and Better Antigen Presentation Capabilities Compared To Those From The Peripheral Blood. <i>Blood</i> , 2013, 122, 4119-4119.	0.6	10
54	Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2012, 158, 589-599.	1.2	45

#	ARTICLE	IF	CITATIONS
55	Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial. <i>Journal of Clinical Oncology</i> , 2012, 30, 1647-1655.	0.8	152
56	Phase II study on combination therapy with CHOP-Zenapax for HTLV-I associated adult T-cell leukaemia/lymphoma (ATLL). <i>Leukemia Research</i> , 2012, 36, 857-861.	0.4	19
57	HCT-CI Is Not a Useful Predictor for Non Relapse Mortality in Older Patients (>60 years old) Receiving RIC Transplant for AML or MDS. <i>Blood</i> , 2012, 120, 4158-4158.	0.6	1
58	Outcome of BEAM-Autologous and BEAM-Alemtuzumab Allogeneic Transplantation in Relapsed Advanced Stage Follicular Lymphoma. <i>Blood</i> , 2012, 120, 2022-2022.	0.6	0
59	Adverse Effect of Very Poor Cytogenetics and Monosomal Karyotype On Outcomes Following T-Deplete Reduced Intensity Conditioned Stem Cell Transplant for MDS and AML. <i>Blood</i> , 2012, 120, 3141-3141.	0.6	0
60	Alemtuzumab-Based Reduced-Intensity Conditioning Allogeneic Transplantation for Myeloma and Plasma Cell Leukemia – A Single-Institution Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 242-245.	0.2	4
61	Two-faced T cells in CLL. <i>Blood</i> , 2011, 117, 5273-5274.	0.6	6
62	Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). <i>Journal of Clinical Oncology</i> , 2011, 29, 108-115.	1.2	108
63	Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. <i>British Journal of Haematology</i> , 2011, 154, 216-222.	1.2	69
64	CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. <i>Leukemia Research</i> , 2011, 35, 750-756.	0.4	60
65	Long-Term Outcomes of Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation (RIC-HSCT) for AML with Myelodysplasia-Related Changes. <i>Blood</i> , 2011, 118, 3079-3079.	0.6	0
66	Pre-Emptive Donor Lymphocyte Infusions (DLI) Lead to High Cure Rates in T-Cell Depleted Allogeneic Haemopoietic Stem Cell Transplants for MDS/AML. <i>Blood</i> , 2011, 118, 660-660.	0.6	5
67	Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. <i>Bone Marrow Transplantation</i> , 2010, 45, 633-639.	1.3	47
68	Interaction with Vascular Endothelium Enhances Survival in Primary Chronic Lymphocytic Leukemia Cells via NF- κ B Activation and <i>De novo</i> Gene Transcription. <i>Cancer Research</i> , 2010, 70, 7523-7533.	0.4	88
69	Direct Evidence for a Chronic Antigen Driven T Cell Response In CLL Lymph Nodes. <i>Blood</i> , 2010, 116, 915-915.	0.6	13
70	A Decade of Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes Following Conditioning with Fludarabine, Busulphan and Alemtuzumab. <i>Blood</i> , 2009, 114, 2266-2266.	0.6	0
71	Two Distinct Co-Culture Systems, Designed to Mimic the Tumor Microenvironment, Induce Remarkably Similar Phenotypic Changes in Primary CLL Cells. <i>Blood</i> , 2009, 114, 2362-2362.	0.6	0
72	Evidence for A Macromolecular Complex in Poor Prognostic CLL That Contains CD38, CD49d, CD44, MMP-9 and ZAP-70. <i>Blood</i> , 2009, 114, 2334-2334.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Tumor-derived IL-6 may contribute to the immunological defect in CLL. <i>Leukemia</i> , 2008, 22, 1084-1087.	3.3	27
74	Sarcoidosis and haematological malignancies: is there an association?. <i>British Journal of Haematology</i> , 2008, 141, 260-262.	1.2	14
75	Outcome of BEAM-autologous and BEAM-alemtuzumab allogeneic transplantation in relapsed advanced stage follicular lymphoma. <i>British Journal of Haematology</i> , 2008, 141, 235-243.	1.2	44
76	CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. <i>Blood</i> , 2008, 111, 5173-5181.	0.6	197
77	Vascular Endothelial Cells Promote the Viability of CLL Cells Via the up-Regulation of Bcl-2 and Bcl-XL. <i>Blood</i> , 2008, 112, 357-357.	0.6	0
78	Lymphoma diagnosis: an update. <i>Clinical Medicine</i> , 2007, 7, 620-624.	0.8	1
79	Acute myeloid leukaemia presenting with mediastinal myeloid sarcoma: Report of three cases and review of literature. <i>Leukemia and Lymphoma</i> , 2007, 48, 290-294.	0.6	19
80	Eczematoid Graft-vs-Host Disease. <i>Archives of Dermatology</i> , 2007, 143, 1157-62.	1.7	55
81	False positive results of galactomannan ELISA assay in haemato-oncology patients: A single centre experience. <i>Journal of Infection</i> , 2007, 55, 201-202.	1.7	5
82	Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: association with chronic graft-versus-host disease and improved overall survival. <i>Bone Marrow Transplantation</i> , 2007, 40, 747-752.	1.3	15
83	Sclerodermatous graft-versus-host disease: clinical spectrum and therapeutic challenges. <i>British Journal of Dermatology</i> , 2007, 156, 1032-1038.	1.4	44
84	Outcomes of patients with haematological malignancies admitted to intensive care unit. A comparative review of allogeneic haematopoietic stem cell transplantation data. <i>British Journal of Haematology</i> , 2007, 136, 448-450.	1.2	26
85	Laser capture microscopy as a tool for the assessment of lineage-specific chimaerism from archived blood and bone marrow films. <i>British Journal of Haematology</i> , 2007, 136, 677-678.	1.2	1
86	Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoietic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. <i>British Journal of Haematology</i> , 2007, 138, 517-526.	1.2	39
87	Toxoplasmosis following alemtuzumab based allogeneic haematopoietic stem cell transplantation. <i>Journal of Infection</i> , 2007, 54, e83-e86.	1.7	21
88	Long Term Outcomes of Adults Undergoing Alemtuzumab-Based Reduced Intensity Conditioning Haematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 1665-1665.	0.6	0
89	Progression Free Survival (PFS) in Alemtuzumab Based RIC Allogeneic Transplantation for Myeloma Is Improved with Use of Pre-Emptive DLI (pDLI).. <i>Blood</i> , 2007, 110, 3034-3034.	0.6	0
90	Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study. <i>Blood</i> , 2006, 107, 1724-1730.	0.6	169

#	ARTICLE	IF	CITATIONS
91	Koebnerizing sclerodermatous graft-versus-host disease caused by donor lymphocyte infusion and interferon- γ . <i>British Journal of Dermatology</i> , 2006, 155, 621-623.	1.4	14
92	Outcomes of alemtuzumab-based reduced intensity conditioning stem cell transplantation using unrelated donors for myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2006, 135, 201-209.	1.2	56
93	Increase in allergy following donor lymphocyte infusions. <i>Bone Marrow Transplantation</i> , 2006, 37, 983-984.	1.3	7
94	Prolonged remission in a case of Richter's transformation of B-cell chronic lymphocytic leukaemia following adoptive immunotherapy. <i>Bone Marrow Transplantation</i> , 2006, 38, 461-462.	1.3	3
95	Incidence and management of hepatic venoocclusive disease in 237 patients undergoing reduced-intensity conditioning (RIC) haematopoietic stem cell transplantation (HSCT). <i>Bone Marrow Transplantation</i> , 2006, 38, 823-824.	1.3	26
96	Lamivudine prophylaxis and treatment of hepatitis B Virus-exposed recipients receiving reduced intensity conditioning hematopoietic stem cell transplants with alemtuzumab. <i>Journal of Medical Virology</i> , 2006, 78, 1560-1563.	2.5	48
97	IL-6 Production by B-CLL Cells Plays a Critical Role in the Inhibition of T Cell Activation and Proliferation and Promotes a Th2 Response in Normal T Lymphocytes.. <i>Blood</i> , 2006, 108, 2808-2808.	0.6	1
98	Restricted MHC Phenotypes in Lymphoproliferative Disorders with Non-Random Immunoglobulin Variable Gene Usage: Evidence for Antigen-Specific Interactions between Tumor and Microenvironment.. <i>Blood</i> , 2006, 108, 2818-2818.	0.6	0
99	Co-Morbidity and Disease Status at the Time of Transplant Predict Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) for Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML).. <i>Blood</i> , 2006, 108, 3108-3108.	0.6	0
100	Tumor supernatant from myeloid malignancies inhibits T-cell apoptosis and cell cycle entry independently. <i>Leukemia</i> , 2005, 19, 1699-1702.	3.3	0
101	Cardiac presentation of ALK positive anaplastic large cell lymphoma. <i>European Journal of Haematology</i> , 2005, 75, 511-514.	1.1	23
102	IL-2/B7.1 (CD80) Fusagene Transduction of AML Blasts by a Self-Inactivating Lentiviral Vector Stimulates T Cell Responses in Vitro: a Strategy to Generate Whole Cell Vaccines for AML. <i>Molecular Therapy</i> , 2005, 11, 120-131.	3.7	49
103	Effect of CD3/CD28 Bead-Activated and Expanded T Cells on Leukemic B Cells in Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2005, 174, 6562-6563.	0.4	12
104	Reduced Intensity Allogeneic Transplantation Using BEAM-Alemtuzumab in Patients with Lymphoid Malignancy: Long Term Results and Impact of Intervention with DLI.. <i>Blood</i> , 2005, 106, 2890-2890.	0.6	9
105	Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Is as Effective in Poor Risk as Standard Risk Acute Myeloid Leukaemia (AML).. <i>Blood</i> , 2005, 106, 2901-2901.	0.6	0
106	Second Reduced Intensity Transplants Are Effective and Well Tolerated in Older Patients with Relapsed Myeloid Malignancies. A Single Centre Report.. <i>Blood</i> , 2005, 106, 5406-5406.	0.6	0
107	Improved Disease Free Survival Following Reduced Intensity Conditioned Allogeneic Stem Cell Transplantation Incorporating Alemtuzumab Compared with Autologous Stem Cell Transplantation in Follicular Lymphoma.. <i>Blood</i> , 2005, 106, 1144-1144.	0.6	0
108	Results of Alemtuzumab-Based Reduced-Intensity Allogeneic Transplantation for Advanced Chronic Lymphocytic Leukemia: A BSBMT Study.. <i>Blood</i> , 2005, 106, 2899-2899.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Antiapoptotic Microenvironment of Acute Myeloid Leukemia. <i>Journal of Immunology</i> , 2004, 173, 6745-6752.	0.4	24
110	Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. <i>Blood</i> , 2004, 104, 1616-1623.	0.6	199
111	BEAM-alemtuzumab reduced-intensity allogeneic stem cell transplantation for lymphoproliferative diseases: GVHD, toxicity, and survival in 65 patients. <i>Blood</i> , 2004, 103, 428-434.	0.6	171
112	Gemtuzumab Ozogamicin with Donor Leucocyte Infusions Is Safe and Effective Therapy for a Subgroup of Relapsed Acute Myeloid Leukaemia and Myelodysplastic Syndrome Following Allogeneic Haemopoietic Stem Cell Transplantation (HSCT).. <i>Blood</i> , 2004, 104, 1806-1806.	0.6	1
113	Analysis of Beam (Carmustine, Etoposide, Cytosine Arabinoside, Melphalan) Versus High Dose Melphalan (HDM) with Autologous Rescue in Multiple Myeloma(MM).. <i>Blood</i> , 2004, 104, 5227-5227.	0.6	2
114	Single Centre Experience of Patients with Haematological Malignancies Admitted to Intensive Care Unit: A Comparative Review of Allogenic Bone Marrow Transplant Data.. <i>Blood</i> , 2004, 104, 1830-1830.	0.6	0
115	Invasive Pulmonary Aspergillosis Is Not a Contraindication to Reduced-Intensity Conditioned Allogeneic Haematopoietic Stem Cell Transplantation (RIC allo-HSCT).. <i>Blood</i> , 2004, 104, 1831-1831.	0.6	0
116	The Acquired CD40L Deficiency in B-CLL Is Reversible and Due To Contact Dependant and Independent Factors.. <i>Blood</i> , 2004, 104, 2813-2813.	0.6	0
117	Response to Peggs et al.. <i>Bone Marrow Transplantation</i> , 2003, 31, 727-727.	1.3	0
118	Reduced-intensity rituximab-BEAM-CAMPATH allogeneic haematopoietic stem cell transplantation for follicular lymphoma is feasible and induces durable molecular remissions. <i>Bone Marrow Transplantation</i> , 2003, 31, 551-557.	1.3	23
119	Reduced-intensity allogeneic hematopoietic stem cell transplantation with alemtuzumab conditioning regimens: survival does not plateau until after day 200. <i>Blood</i> , 2003, 101, 779-780.	0.6	9
120	Fatal donor-derived Epstein-Barr virus-associated post-transplant lymphoproliferative disorder following reduced intensity volunteer-unrelated bone marrow transplant for myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2002, 29, 867-869.	1.3	17
121	Heparin Binds to Murine Leukemia Virus and Inhibits Env-Independent Attachment and Infection. <i>Journal of Virology</i> , 2002, 76, 6909-6918.	1.5	41
122	Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. <i>Blood</i> , 2002, 100, 1715-1720.	0.6	117
123	Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens. <i>British Journal of Haematology</i> , 2002, 119, 144-154.	1.2	79
124	The upregulation of CC chemokine receptor 7 and the increased migration of maturing dendritic cells to macrophage inflammatory protein 3 β and secondary lymphoid chemokine is mediated by the p38 stress-activated protein kinase pathway. <i>British Journal of Haematology</i> , 2002, 119, 826-829.	1.2	16
125	The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. <i>Blood</i> , 2000, 96, 3932-3938.	0.6	319
126	The PI3 kinase, p38 SAP kinase, and NF- κ B signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. <i>Blood</i> , 2000, 96, 1039-1046.	0.6	405

#	ARTICLE	IF	CITATIONS
127	In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. <i>Blood</i> , 2000, 96, 2419-2425.	0.6	483
128	Effect of Changes in Expression of the Amphotropic Retroviral Receptor PiT-2 on Transduction Efficiency and Viral Titer: Implications for Gene Therapy. <i>Human Gene Therapy</i> , 2000, 11, 587-595.	1.4	19
129	The PI3 kinase, p38 SAP kinase, and NF- κ B signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. <i>Blood</i> , 2000, 96, 1039-1046.	0.6	21
130	In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation. <i>Blood</i> , 2000, 96, 2419-2425.	0.6	6
131	Outcome of secondary myeloid malignancy in Hodgkin's disease: the BNLI experience. <i>European Journal of Haematology</i> , 1998, 61, 109-112.	1.1	7
132	Granulocyte-macrophage colony stimulating factor receptor α and β chain complexes can form both high and intermediate affinity functional receptors. <i>British Journal of Haematology</i> , 1997, 98, 809-818.	1.2	3
133	10 Anti-sense and gene therapy approaches to the treatment of lymphomas. <i>Best Practice and Research: Clinical Haematology</i> , 1996, 9, 819-834.	1.1	3
134	A randomized trial of empirical antibiotic therapy with one of four β -lactam antibiotics in combination with netilmicin in febrile neutropenic patients. <i>Journal of Antimicrobial Chemotherapy</i> , 1988, 22, 237-247.	1.3	12